Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS

Neurology

Volumn 51, Issue 2, 1998, Pages 529-534

  Frederiksen, J L ^a   Nielsen, P M ^a   Olesen, J ^a   Sellebjerg, Finn ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

EID: 0344352481     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.51.2.529     Document Type: Article

References (20)

1. Durelli L, Cocito D, Riccio A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis. Neurology 1986;36:238-243.
2. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis, 1: clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-516.
3. Beck RW, Cleary PA, Anderson Jr MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992;326:581-588.
4. Goodin DS. The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review. Neurology 1991;41:980-985.
5. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
6. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
7. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
8. Sipe JC, Knobler RL, Braheny SL, et al. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984;34: 1368-1372.
9. Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993;56:1219-1220.
10. Barnes D, Hughes RAC, Morris RW, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997;349:902-906.
11. Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don't agree: cross-sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ 1997;314:1580-1583.
12. Barnes D, Hughes RAC. Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis. Lancet 1997;349: 1697. Letter.
13. Beck RW, Cleary PA. Optic neuritis treatment trial: one-year follow-up results. Arch Ophthalmol 1993;111:773-775.
14. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993;329:1764-1769.
15. Kupersmith MJ, Kaufman D, Paty DW, et al. Megadose corticosteroids in multiple sclerosis. Neurology 1994;44:14. Editorial.
16. Silberberg DH. Corticosteroids and optic neuritis. N Engl J Med 1993;329:1808-1810. Editorial.
17. Goodkin DE, Rudick RA, Kinkel R, Ransohoff RM. Corticosteroids and optic neuritis. Neurology 1993;43:631-632. Letter.
18. Goodin DS. Corticosteroids and optic neuritis. Neurology 1993;43:632-633. Letter.
19. Lyons PR, Newman PK, Saunders M. Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects. J Neurol Neurosurg Psychiatry 1988;51:285-287.
20. Chrousos GA, Kattah JC, Beck RW, Cleary PA. Side effects of glucocorticoid treatment. JAMA 1993;269:2110-2112.